The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.

The government is backing groundbreaking research to detect bowel cancer earlier and more effectively. Recent investments include £2.4 million for an AI blood test that can spot cancer with over 99% ...

People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed ...

The updated guidance for people aged 16 and over recommends using smaller amounts of intravenous fluid initially for those at risk of serious illness or death due to sepsis. Patients should be ...

Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer TA1110 19 November 2025 19 November 2025 Trastuzumab deruxtecan for treating ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...

Evidence-based recommendations on secukinumab (Cosentyx) for moderate to severe plaque psoriasis in children and young people aged 6 to 17 years. Next review: This guidance will be reviewed if there ...

Decisions about updating our guidance are made by NICE’s prioritisation board. For more information on the principles and process, see NICE-wide topic prioritisation: the manual. For information about ...

This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is ...

This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give ...